Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Irbesartan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 3/20 | 0.74 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.74 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.74 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | GAA | P10253 | 1/20 | 0.74 |
| ▸ | EDNRA | P25101 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | HTR2B | P41595 | 1/20 | 0.74 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.74 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.74 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.74 |
| ▸ | ACHE | P22303 | 3/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Irbesartan SCHEMBL2212239 | 1.00 | AGTR1 (0.74) | AGTR1LTB4R2ABCC3ABCC4ABCB11 | |
| Irbesartan SCHEMBL3376730 | 0.99 | AGTR1 (0.73) | AGTR1LTB4R2ABCC3ABCC4ABCB11 | |
| Irbesartan SCHEMBL3098203 | 0.99 | AGTR1 (0.73) | AGTR1LTB4R2ABCC3ABCC4ABCB11 | |
| Irbesartan SCHEMBL4520818 | 0.99 | AGTR1 (0.73) | AGTR1LTB4R2ABCC3ABCC4ABCB11 | |
| Irbesartan SCHEMBL3373783 | 0.99 | AGTR1 (0.73) | AGTR1LTB4R2ABCC3ABCC4ABCB11 | |
| SCHEMBL683789 | 0.99 | AGTR1 (0.73) | AGTR1LTB4R2ABCC3ABCC4ABCB11 | |
| Irbesartan SCHEMBL2208976 | 0.99 | AGTR1 (0.73) | AGTR1LTB4R2ABCC3ABCC4ABCB11 | |
| Irbesartan SCHEMBL4726034 | 0.99 | AGTR1 (0.73) | AGTR1LTB4R2ABCC3ABCC4ABCB11 | |
| Irbesartan SCHEMBL4726870 | 0.99 | AGTR1 (0.73) | AGTR1LTB4R2ABCC3ABCC4ABCB11 | |
| SCHEMBL683876 | 0.99 | AGTR1 (0.73) | AGTR1LTB4R2ABCC3ABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 35899 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747238-A1 | PROCESS FOR PREPARING INTERMEDIATES OF SARTAN ACTIVE COMPOUNDS | Sanofi (FR) | 2026-05-27 | — | — | EP | claimed |
| CN-122010845-A | Method for recovering irbesartan intermediate from irbesartan mother liquor | 珠海润都制药股份有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| US-20260115231-A1 | TREATMENT OF CEREBRAL PALSY USING FIBROBLASTS | SPINALCYTE LLC (US) | 2026-04-30 | — | — | US | claimed |
| US-12605384-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20260097039-A1 | METHODS FOR TREATING A FATTY LIVER DISEASE | MADRIGAL PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-20260083726-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS, CHEMOTHERAPEUTIC AGENTS, AND ANTI-FIBROTIC AGENTS | NOVOCURE GMBH (CH) | 2026-03-26 | — | — | US | claimed |
| US-5629331-A | 2-BUTYL-3-TETRAZOLYLBIPHENYLYLMETHYL-1,3-DIAZASPIRONONENONE MADE BY REACTING CORRESPONDING NITRILE WITH ALKALINE AZIDE AND TRIETHYLAMINE HYDROCHLORIDE IN INERT POLAR APROTIC SOLVENT, NEUTRALIZING SALT, CRYSTALLIZING IN ONE OF TWO WAYS | SANOFI (FR) | 1997-05-13 | — | — | US | claimed |
| CN-1144656-A | Pharmaceutical composition containing irbesartan | BRISTOL MYERS SQUIBB CO (US) | 1997-03-12 | — | — | CN | claimed |
| WO-1997002032-A1 | METHOD OF TREATING RENAL DISEASE USING AN ACE INHIBITOR AND AN AII ANTAGONIST | MERCK & CO., INC. (US) | 1997-01-23 | — | — | WO | claimed |
| WO-1996040255-A2 | METHOD TO TREAT CARDIOFIBROSIS WITH A COMBINATION THERAPY OF AN ANGIOTENSIN II ANTAGONIST AND AN EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040257-A1 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040258-A2 | SPIRONOLACTONE AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040256-A1 | METHOD TO TREAT CARDIOFIBROSIS WITH A COMBINATION OF AN ANGIOTENSIN II ANTAGONIST AND SPIRONOLACTONE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| EP-0747050-A1 | Pharmaceutical compositions containing irbesartan | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-11 | — | — | EP | claimed |
| EP-0708103-A1 | Process for the preparation of a tetrazole derivative in two crystalline forms and a new crystalline form of this derivative | SANOFI (FR) | 1996-04-24 | — | — | EP | claimed |
| EP-0475898-A1 | Azacyclic compounds | CIBA-GEIGY AG (CH) | 1992-03-18 | — | — | EP | claimed |